Protective effect of melatonin against Adriamycin‑induced cardiotoxicity

Zhang,Yan; Li,Lixin; Xiang,Cheng; Ma,Zhiqian; Ma,Tian; Zhu,Shuchai

doi:10.3892/etm.2013.989

Protective effect of melatonin against Adriamycin‑induced cardiotoxicity

Authors:
- Yan Zhang
- Lixin Li
- Cheng Xiang
- Zhiqian Ma
- Tian Ma
- Shuchai Zhu
View Affiliations

Affiliations: Department of Oncology, The First Hospital of Shijiazhuang, Shijiazhuang, Hebei 050010, P.R. China, Department of Clinical Laboratory, The First Hospital of Shijiazhuang, Shijiazhuang, Hebei 050010, P.R. China, Department of Pharmacy, The First Hospital of Shijiazhuang, Shijiazhuang, Hebei 050010, P.R. China, Department of Radiotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
Published online on: March 6, 2013 https://doi.org/10.3892/etm.2013.989
Pages: 1496-1500

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this in vivo study was to explore the protective properties of melatonin against Adriamycin‑induced myocardial toxicity. A rat model of breast cancer was established and the rats were randomly divided into the blank group (Blank), the solvent group [Diss; dehydrated alcohol: physiological saline (1:9)], the Adriamycin group (ADM), the melatonin group (MLT) and the melatonin + Adriamycin group (M+A). The concentrations of lipid peroxide (LPO), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in myocardial tissues were detected, the changes in myocardial tissues were observed using light microscopy and electron microscopy, and the 1-month survival rates of each group of rats were compared. Breast cancer was established in 116 rats. In the ADM group, the concentration of LPO was higher and the concentrations of SOD and GSH-Px were significantly lower than those in the blank group. In the M+A group, compared with the ADM group, the concentration of LPO was lower (P<0.05) and the concentrations of SOD and GSH-Px were higher (P<0.05). It was observed using light and electron microscopy that the myocardial injuries to the M+A group were significantly alleviated in comparison with those in the ADM group; the 1-month survival rate in the M+A group was higher than that in the ADM group. Melatonin may have a protective role in the myocardium by reducing Adriamycin‑induced myocardial oxidative damage.

View Figures

View References

1.	Rock E and DeMichele A: Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivors. J Nutr. 133:3785S–3793S. 2003.PubMed/NCBI
2.	Billingham ME, Mason JW, Bristow MR and Daniels JR: Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 62:865–872. 1978.PubMed/NCBI
3.	Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME and Harrison DC: Early anthracycline cardiotoxicity. Am J Med. 65:823–832. 1978. View Article : Google Scholar
4.	Chicco AJ, Schneider CM and Hayward R: Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart. Am J Physiol Regul Integr Comp Physiol. 289:R424–R431. 2005. View Article : Google Scholar : PubMed/NCBI
5.	Chicco AJ, Schneider CM and Hayward R: Exercise training attenuates acute doxorubicin-induced cardiac dysfunction. J Cardiovasc Pharmacol. 47:182–189. 2006. View Article : Google Scholar : PubMed/NCBI
6.	Hydock DS, Lien CY, Schneider CM and Hayward R: Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction. Med Sci Sports Exerc. 40:808–817. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S and Noonan DM: Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 102:14–25. 2010. View Article : Google Scholar : PubMed/NCBI
8.	Lissoni P: Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent. Pathol Biol (Paris). 55:198–200. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Jawed S, Kim B, Ottenhof T, Brown GM, Werstiuk ES and Niles LP: Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation. Eur J Pharmacol. 560:17–22. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Lemus-Wilson A, Kelly PA and Blask DE: Melatonin blocks the stimulation effects of prolactin and human breast cancer cell growth in culture. Br J Cancer. 72:1435–1440. 1995. View Article : Google Scholar
11.	Sánchez-Barceló EJ, Cos S, Mediavilla D, Martínez-Campa C, González A and Alonso-González C: Melatonin-estrogen interactions in breast cancer. J Pineal Res. 38:217–222. 2005.
12.	Zhang Y, Zhu S and Liu J: The reverse effect and mechanism of melatonin on breast carcinoma cell line MCF-7/ADM resistant to Adriamycin. Chinese Journal of Clinical Oncology. 36:291–295. 2009.(In Chinese).
13.	Zhang Y, Zhu S and Zhao W: The effect of melatonin on the sensitivity of ER⁺breast carcinoma cell line MCF-7 to Adriamycin and its mechanism. Chinese Journal of Clinical Oncology. 36:1243–1247. 2009.(In Chinese).
14.	Reiter RJ, Tan DX, Manchester LC, Paredes SD, Mayo JC and Sainz RM: Melatonin and reproduction revisited. Biol Reprod. 81:445–456. 2009. View Article : Google Scholar : PubMed/NCBI
15.	Sener G, Jahovic N, Tosun O, Atasoy BM and Yeğen BC: Melatonin ameliorates ionizing radiation-induced oxidative organ damage in rats. Life Sci. 74:563–572. 2003. View Article : Google Scholar : PubMed/NCBI
16.	Reiter RJ, Guerrero JM, Escames G, Pappolla MA and Acuña-Castroviejo D: Prophylactic actions of melatonin in oxidative neurotoxicity. Ann N Y Acad Sci. 825:70–78. 1997. View Article : Google Scholar : PubMed/NCBI
17.	Okatani Y, Wakatsuki A and Kaneda C: Melatonin increases activities of glutathione peroxidase and superoxide dismutase in fetal rat brain. J Pineal Res. 28:89–96. 2000. View Article : Google Scholar : PubMed/NCBI
18.	Reiter RJ, Acuña-Castroviejo D, Tan DX and Burkhardt S: Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann N Y Acad Sci. 939:200–215. 2001. View Article : Google Scholar : PubMed/NCBI
19.	Hardeland R, Pandi-Perumal SR and Cardinali DP: Melatonin. Int J Biochem Cell Biol. 38:313–316. 2006. View Article : Google Scholar
20.	Ganguly K, Kundu P, Banerjee A, Reiter RJ and Swarnakar S: Hydrogen peroxide-mediated downregulation of matrix metalloprotease-2 in indomethacin-induced acute gastric ulceration is blocked by melatonin and other antioxidants. Free Radic Biol Med. 41:911–925. 2006. View Article : Google Scholar
21.	Bruck R, Aeed H, Avni Y, et al: Melatonin inhibits nuclear factor kappa B activation and oxidative stress and protects against thioacetamide induced liver damage in rats. J Hepatol. 40:86–93. 2004. View Article : Google Scholar : PubMed/NCBI
22.	Yurtcu E, Guney Y, Ergun MA, et al: Lack of a time-dependent effect of melatonin on radiation-induced apoptosis in cultured rat lymphocytes. Cell Biol Int. 31:1144–1149. 2007. View Article : Google Scholar : PubMed/NCBI
23.	Russo J, Tay LK and Russo IH: Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat. 2:5–73. 1982. View Article : Google Scholar : PubMed/NCBI
24.	Dagar S, Sekosan M, Rubinstein I and Onyüksel H: Detection of VIP receptors in MNU-induced breast cancer in rats: implications for breast cancer targeting. Breast Cancer Res Treat. 65:49–54. 2001. View Article : Google Scholar : PubMed/NCBI
25.	Sener-Muratoğlu G, Paskaloğlu K, Arbak S, Hürdağ C and Ayanoğlu-Dülger G: Protective effect of famotidine, omeprazole, and melatonin against acetylsalicylic acid-induced gastric damage in rats. Dig Dis Sci. 46:318–330. 2001.PubMed/NCBI
26.	Maestroni GJ: The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs. 10:467–476. 2001. View Article : Google Scholar : PubMed/NCBI
27.	Wang WZ, Fang XH, Stephenson LL, et al: Microcirculatory effects of melatonin in rat skeletal muscle after prolonged ischemia. J Pineal Res. 39:57–65. 2005. View Article : Google Scholar : PubMed/NCBI
28.	Topal T, Oter S, Korkmaz A, et al: Exogenously administered and endogenously produced melatonin reduce hyperbaric oxygen-induced oxidative stress in rat lung. Life Sci. 75:461–467. 2004. View Article : Google Scholar
29.	Fisher PW, Salloum F, Das A, et al: Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation. 111:1601–1610. 2005. View Article : Google Scholar : PubMed/NCBI
30.	Floyd JD, Nguyen DT, Lobins RL, et al: Cardiotoxicity of cancer therapy. J Clin Oncol. 23:7685–7696. 2005. View Article : Google Scholar : PubMed/NCBI
31.	Mirunalini S, Karthishwaran K, Dhamodharan G and Shalini M: Melatonin attenuates lipid peroxidation and enhances circulatory antioxidants during mammary carcinogenesis in rats. J Biochem Tech. 2:171–174. 2010.
32.	Reiter RJ and Tan DX: Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart. Cardiovasc Res. 58:10–19. 2003. View Article : Google Scholar : PubMed/NCBI
33.	Lissoni P, Barni S, Mandalá M, Ardizzoia A, Paolorossi F, et al: Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer. 35:1688–1692. 1999. View Article : Google Scholar
34.	Sánchez-Suárez P, Ostrosky-Wegman P, Gallegos-Hernández F, et al: DNA damage in peripheral blood lymphocytes in patients during combined chemotherapy for breast cancer. Mutat Res. 640:8–15. 2008.PubMed/NCBI
35.	Lissoni P: Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol Biol (Paris). 55:201–204. 2007. View Article : Google Scholar : PubMed/NCBI